Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 229

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 229
---
 our generally applicable disciplinary rules.  |

| 113 |

Dmitry Zamoryakhin.We
previously entered into a contract of employment, or the Contract of Employment, with Dr. Zamoryakhin. The Contract of Employment
was effective as of July 12, 2021 and provided for Dr. Zamoryakhin’s base salary, incentive compensation benefits, and compensation
surrounding a termination of his employment. The Contract of Employment was terminable by either Dr. Zamoryakhin or the Company
with six months’ prior notice.

The Contract of Employment
provided for an initial base salary of £205,000, which was subject to adjustment, and also included an initial bonus target of 30%
of Dr. Zamoryakhin’s annual base salary. Dr. Zamoryakhin’s base salary was increased to £215,000 effective
as of April 1, 2022. In addition to base salary and bonus, the Contract of Employment provided for additional benefits, such as a 10%
pension contribution, medical insurance, vacation benefits and any other additional benefits as determined by the Board of Directors from
time to time.

Dr. Zamoryakhin also agreed
that, for a period of six months following his termination (as reduced by any “garden leave” period), he would not compete
with the Company, directly or indirectly, or solicit any customer, prospective customer or key employee. The Contract of Employment
included provisions related to confidentiality and the non-disclosure of information and assignment of inventions. Among other
things, these provisions prohibit Dr. Zamoryakhin from disclosing any of our proprietary and confidential information received during
the course of employment and require Dr. Zamoryakhin to assign to us any inventions conceived or developed during the course of his employment.

The Contract of Employment
provided that we will pay Dr. Zamoryakhin his normal salary during any notice period prior to termination. We are also permitted
to terminate Dr. Zamoryakhin’s employment effective immediately, without notice or payment, if Dr. Zamoryakhin is found guilty of
any fundamental or repudiatory breach of contract or any breach of the disciplinary rules applicable to Dr. Zamoryakhin.

On July 4, 2024, Dr. Zamoryakhin
departed the Company. In connection with his departure, Dr. Zamoryakhin and the Company entered into a settlement agreement, pursuant
to which, among other things, Dr. Zam